Seroprevalence of antibody to varicella among Somali refugees

Lana J. Nysse, Norman A. Pinsky, Jeffrey P. Bratberg, Azra Y. Babar-Weber, Terri T. Samuel, Esther H. Krych, Aaron W. Ziegler, Mahamoud A. Jimale, Robert A. Vierkant, Robert M. Jacobson, Gregory A. Poland

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

OBJECTIVES: To determine the seroprevalence of varicella antibody among recent Somali refugees living in Olmsted County, Minnesota, and to estimate the risk of varicella-zoster virus (VZV) infection in this group. SUBJECTS AND METHODS: We obtained blood samples from the study subjects, along with demographic information, immunization records, and vaccine-preventable disease history. Serum samples were tested using a whole-virus IgG VZV-specific commercial enzyme-linked immunosorbent assay kit. This study was completed in 1998. RESULTS: Overall, 200 Somali refugees, comprising 33 extended families, were interviewed, with 193 providing adequate blood samples. Thirty-five subjects (18%) were seronegative for varicella. Males had a significantly higher seronegativity rate (25% [n=23]) compared with females (12% [n=12]; P=.02); however, this association disappeared after adjustment for age and varicella infection history. Five percent (5/92) of adults were seronegative compared with 30% (30/101) of all children (P<.001). Eight percent (5/61) of the adult females were seronegative, whereas none (0/31) of the adult males were seronegative. Conversely, 38% (23/60) of male children were seronegative compared with 17% (7/41) of female children (P<.001). CONCLUSION: These results demonstrate a high prevalence of varicella seronegativity among Somali refugees who have immigrated to an endemic area. We recommend instituting improved education regarding varicella among Somali communities and increasing vaccine uptake or routine testing for serum varicella antibody to prevent VZV-related morbidity and mortality, particularly in adolescents, adult refugees, and women of childbearing age.

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
JournalMayo Clinic Proceedings
Volume82
Issue number2
DOIs
StatePublished - 2007

Fingerprint

Refugees
Chickenpox
Seroepidemiologic Studies
Human Herpesvirus 3
Antibodies
Vaccines
Virus Diseases
Serum
Immunization
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Demography
Viruses
Morbidity
Education
Mortality
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nysse, L. J., Pinsky, N. A., Bratberg, J. P., Babar-Weber, A. Y., Samuel, T. T., Krych, E. H., ... Poland, G. A. (2007). Seroprevalence of antibody to varicella among Somali refugees. Mayo Clinic Proceedings, 82(2), 175-180. https://doi.org/10.4065/82.2.175

Seroprevalence of antibody to varicella among Somali refugees. / Nysse, Lana J.; Pinsky, Norman A.; Bratberg, Jeffrey P.; Babar-Weber, Azra Y.; Samuel, Terri T.; Krych, Esther H.; Ziegler, Aaron W.; Jimale, Mahamoud A.; Vierkant, Robert A.; Jacobson, Robert M.; Poland, Gregory A.

In: Mayo Clinic Proceedings, Vol. 82, No. 2, 2007, p. 175-180.

Research output: Contribution to journalArticle

Nysse, LJ, Pinsky, NA, Bratberg, JP, Babar-Weber, AY, Samuel, TT, Krych, EH, Ziegler, AW, Jimale, MA, Vierkant, RA, Jacobson, RM & Poland, GA 2007, 'Seroprevalence of antibody to varicella among Somali refugees', Mayo Clinic Proceedings, vol. 82, no. 2, pp. 175-180. https://doi.org/10.4065/82.2.175
Nysse LJ, Pinsky NA, Bratberg JP, Babar-Weber AY, Samuel TT, Krych EH et al. Seroprevalence of antibody to varicella among Somali refugees. Mayo Clinic Proceedings. 2007;82(2):175-180. https://doi.org/10.4065/82.2.175
Nysse, Lana J. ; Pinsky, Norman A. ; Bratberg, Jeffrey P. ; Babar-Weber, Azra Y. ; Samuel, Terri T. ; Krych, Esther H. ; Ziegler, Aaron W. ; Jimale, Mahamoud A. ; Vierkant, Robert A. ; Jacobson, Robert M. ; Poland, Gregory A. / Seroprevalence of antibody to varicella among Somali refugees. In: Mayo Clinic Proceedings. 2007 ; Vol. 82, No. 2. pp. 175-180.
@article{5985a9dc6fa54cb9b6ba1eef4f3550fd,
title = "Seroprevalence of antibody to varicella among Somali refugees",
abstract = "OBJECTIVES: To determine the seroprevalence of varicella antibody among recent Somali refugees living in Olmsted County, Minnesota, and to estimate the risk of varicella-zoster virus (VZV) infection in this group. SUBJECTS AND METHODS: We obtained blood samples from the study subjects, along with demographic information, immunization records, and vaccine-preventable disease history. Serum samples were tested using a whole-virus IgG VZV-specific commercial enzyme-linked immunosorbent assay kit. This study was completed in 1998. RESULTS: Overall, 200 Somali refugees, comprising 33 extended families, were interviewed, with 193 providing adequate blood samples. Thirty-five subjects (18{\%}) were seronegative for varicella. Males had a significantly higher seronegativity rate (25{\%} [n=23]) compared with females (12{\%} [n=12]; P=.02); however, this association disappeared after adjustment for age and varicella infection history. Five percent (5/92) of adults were seronegative compared with 30{\%} (30/101) of all children (P<.001). Eight percent (5/61) of the adult females were seronegative, whereas none (0/31) of the adult males were seronegative. Conversely, 38{\%} (23/60) of male children were seronegative compared with 17{\%} (7/41) of female children (P<.001). CONCLUSION: These results demonstrate a high prevalence of varicella seronegativity among Somali refugees who have immigrated to an endemic area. We recommend instituting improved education regarding varicella among Somali communities and increasing vaccine uptake or routine testing for serum varicella antibody to prevent VZV-related morbidity and mortality, particularly in adolescents, adult refugees, and women of childbearing age.",
author = "Nysse, {Lana J.} and Pinsky, {Norman A.} and Bratberg, {Jeffrey P.} and Babar-Weber, {Azra Y.} and Samuel, {Terri T.} and Krych, {Esther H.} and Ziegler, {Aaron W.} and Jimale, {Mahamoud A.} and Vierkant, {Robert A.} and Jacobson, {Robert M.} and Poland, {Gregory A.}",
year = "2007",
doi = "10.4065/82.2.175",
language = "English (US)",
volume = "82",
pages = "175--180",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Seroprevalence of antibody to varicella among Somali refugees

AU - Nysse, Lana J.

AU - Pinsky, Norman A.

AU - Bratberg, Jeffrey P.

AU - Babar-Weber, Azra Y.

AU - Samuel, Terri T.

AU - Krych, Esther H.

AU - Ziegler, Aaron W.

AU - Jimale, Mahamoud A.

AU - Vierkant, Robert A.

AU - Jacobson, Robert M.

AU - Poland, Gregory A.

PY - 2007

Y1 - 2007

N2 - OBJECTIVES: To determine the seroprevalence of varicella antibody among recent Somali refugees living in Olmsted County, Minnesota, and to estimate the risk of varicella-zoster virus (VZV) infection in this group. SUBJECTS AND METHODS: We obtained blood samples from the study subjects, along with demographic information, immunization records, and vaccine-preventable disease history. Serum samples were tested using a whole-virus IgG VZV-specific commercial enzyme-linked immunosorbent assay kit. This study was completed in 1998. RESULTS: Overall, 200 Somali refugees, comprising 33 extended families, were interviewed, with 193 providing adequate blood samples. Thirty-five subjects (18%) were seronegative for varicella. Males had a significantly higher seronegativity rate (25% [n=23]) compared with females (12% [n=12]; P=.02); however, this association disappeared after adjustment for age and varicella infection history. Five percent (5/92) of adults were seronegative compared with 30% (30/101) of all children (P<.001). Eight percent (5/61) of the adult females were seronegative, whereas none (0/31) of the adult males were seronegative. Conversely, 38% (23/60) of male children were seronegative compared with 17% (7/41) of female children (P<.001). CONCLUSION: These results demonstrate a high prevalence of varicella seronegativity among Somali refugees who have immigrated to an endemic area. We recommend instituting improved education regarding varicella among Somali communities and increasing vaccine uptake or routine testing for serum varicella antibody to prevent VZV-related morbidity and mortality, particularly in adolescents, adult refugees, and women of childbearing age.

AB - OBJECTIVES: To determine the seroprevalence of varicella antibody among recent Somali refugees living in Olmsted County, Minnesota, and to estimate the risk of varicella-zoster virus (VZV) infection in this group. SUBJECTS AND METHODS: We obtained blood samples from the study subjects, along with demographic information, immunization records, and vaccine-preventable disease history. Serum samples were tested using a whole-virus IgG VZV-specific commercial enzyme-linked immunosorbent assay kit. This study was completed in 1998. RESULTS: Overall, 200 Somali refugees, comprising 33 extended families, were interviewed, with 193 providing adequate blood samples. Thirty-five subjects (18%) were seronegative for varicella. Males had a significantly higher seronegativity rate (25% [n=23]) compared with females (12% [n=12]; P=.02); however, this association disappeared after adjustment for age and varicella infection history. Five percent (5/92) of adults were seronegative compared with 30% (30/101) of all children (P<.001). Eight percent (5/61) of the adult females were seronegative, whereas none (0/31) of the adult males were seronegative. Conversely, 38% (23/60) of male children were seronegative compared with 17% (7/41) of female children (P<.001). CONCLUSION: These results demonstrate a high prevalence of varicella seronegativity among Somali refugees who have immigrated to an endemic area. We recommend instituting improved education regarding varicella among Somali communities and increasing vaccine uptake or routine testing for serum varicella antibody to prevent VZV-related morbidity and mortality, particularly in adolescents, adult refugees, and women of childbearing age.

UR - http://www.scopus.com/inward/record.url?scp=33846697327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846697327&partnerID=8YFLogxK

U2 - 10.4065/82.2.175

DO - 10.4065/82.2.175

M3 - Article

C2 - 17290724

AN - SCOPUS:33846697327

VL - 82

SP - 175

EP - 180

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -